Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom

被引:33
作者
Isbister, Geoffrey K. [1 ,2 ]
Woods, David [1 ]
Alley, Steven [1 ]
O'Leary, Margaret A.
Seldon, Michael
Lincz, Lisa F. [1 ]
机构
[1] Univ Newcastle, Fac Hlth, Newcastle, NSW 2308, Australia
[2] Charles Darwin Univ, Trop Toxinol Unit, Menzies Sch Hlth Res, Darwin, NT 0909, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Thrombin potential; Antivenom; Snake; Procoagulant venom; Prothrombin activator; COAGULATION-FACTOR-XA; AUSTRALIAN BROWN SNAKE; PROTHROMBIN ACTIVATOR; TROPIDECHIS-CARINATUS; PSEUDONAJA; COAGULOPATHY; PURIFICATION; SIMILARITY; TEXTILIS; PLASMA;
D O I
10.1016/j.toxicon.2010.03.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Venom-induced consumption coagulopathy occurs in snake envenoming worldwide but the interaction between procoagulant snake venoms and human coagulation remains poorly understood. We aimed to evaluate an assay using endogenous thrombin potential (ETP) to investigate the procoagulant properties of a range of Australian whole venoms in human plasma and compared this to traditional clotting and prothrombinase activity studies. We developed a novel modification of ETP using procoagulant snake venoms to trigger thrombin production. This was used to characterise the relative potency, calcium and clotting factor requirements of five important Australian snake venoms and efficacy of commercial antivenom, and compared this to prothrombinase activity and clotting assays. All five venoms initiated thrombin generation in the absence and presence of calcium. Pseudonaja textilis (Brown snake; p < 0.0001), Hoplocephalus stephensii (Stephen's-banded snake; p < 0.0001) and Notechis scutatus (tiger snake; p = 0.0073) all had statistically significant increases in ETP with calcium. Venom potency varied between assays, with ETP ranging from least potent with Oxyuranus scutellatus (Taipan) venom to intermediate with N. scutatus and H. stephensii venoms to most potent with P. textilis and Tropidechis carinatus (Rough-scale snake) venoms. ETPs for N. scutatus, T carinatus and H. stephensii venoms were severely reduced with factor V deficient plasma. Antivenom neutralized the thrombin generating capacity but not prothrombin substrate cleaving ability of the venoms. Contrary to previous studies using clotting tests and factor Xa substrates, these venoms differ in calcium requirement. ETP is a useful assay to investigate mechanisms of other procoagulant venoms and is a robust method of assessing antivenom efficacy. Crown Copyright (C) 2010 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:75 / 85
页数:11
相关论文
共 32 条
[11]   ANALYSIS OF THROMBIN GENERATION IN PLASMA [J].
KESSELS, H ;
WILLEMS, G ;
HEMKER, HC .
COMPUTERS IN BIOLOGY AND MEDICINE, 1994, 24 (04) :277-288
[12]  
Kini RM, 2001, HAEMOSTASIS, V31, P218
[13]   Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden [J].
Lincz, Lisa F. ;
Lonergan, Amy ;
Scorgie, Fiona E. ;
Rowlings, Phillip ;
Gibson, Richard ;
Lawrie, Andrew ;
Seldon, Michael .
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, 2006, 35 (06) :435-439
[14]   Antivenom development in Australia [J].
Madaras, F ;
Mirtschin, PJ ;
Kuchel, T .
TOXIN REVIEWS, 2005, 24 (01) :79-94
[15]   Practical applications of snake venom toxins in haemostasis [J].
Marsh, N ;
Williams, V .
TOXICON, 2005, 45 (08) :1171-1181
[16]  
MARSHALL LR, 1983, THROMB HAEMOSTASIS, V50, P707
[17]   Brown snakes (Pseudonaja genus): Venom yields, prothrombin activator neutralization and implications affecting antivenom usage [J].
Masci, PP ;
Mirtschin, PJ ;
Nias, TN ;
Turnbull, RK ;
Kuchel, TR ;
Whitaker, AN .
ANAESTHESIA AND INTENSIVE CARE, 1998, 26 (03) :276-281
[18]  
MASCI PP, 1988, BIOCHEM INT, V17, P825
[19]   Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming:: Detecting venom, antivenom and venom-antivenom complexes [J].
O'Leary, Margaret A. ;
Isbister, Geoffrey K. ;
Schneider, Jennifer J. ;
Brown, Simon G. A. ;
Currie, Bart J. .
TOXICON, 2006, 48 (01) :4-11
[20]  
OLEARY MA, 2009, J PHARM TOXICOLOGICA